[1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-60.10.1056/NEJM199803263381301]Search in Google Scholar
[2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997; 315:1194-9.10.1136/bmj.315.7117.1194]Search in Google Scholar
[3. Sungkanuparph S, Kiertiburanakul S, Manosuthi W, Kiatatchasai W, Vibhagool A. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability. Int J STD AIDS. 2005; 16:243-6.10.1258/0956462053420121]Open DOISearch in Google Scholar
[4. Kiertiburanakul S, Sungkanuparph S, Rattanasiri S, Manosuthi W, Vibhagool A, Thakkinstian A. Virological and immunological responses of efavirenzbased HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3. J Med Assoc Thai. 2006; 89:1381-7.]Search in Google Scholar
[5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosiscoinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43:42-6.10.1097/01.qai.0000230521.86964.86]Search in Google Scholar
[6. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007; 5: 355-60.10.2174/157016207780636551]Search in Google Scholar
[7. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004; 87:760-7.]Search in Google Scholar
[8. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+ nevirapine) in treatment-naive adult HIV patients. Southeast Asian J Trop Med Public Health. 2005; 36: 362-9.]Search in Google Scholar
[9. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health. 2006; 37: 704-15.]Search in Google Scholar
[10. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, et al; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008; 1:925-35.]Search in Google Scholar
[11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 11 April 2010.]Search in Google Scholar
[12. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents - November 2009; 1-24. Available at http://www.who.int/HIV/pub/arv/rapid_advice_art.pdf. Accessed 11 April 2010.]Search in Google Scholar
[13. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIVinfected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006; 53:357-63.10.1016/j.jinf.2006.01.002]Search in Google Scholar
[14. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 2007; 45:595-6.10.1097/QAI.0b013e318061b5eb]Search in Google Scholar
[15. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, Thakkinstian A. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiarycare- based study. J Med Assoc Thai. 2004; 87: 1349-54.]Search in Google Scholar
[16. Sungkanuparph S, Wongprasit P, Manosuthi W, Atamasirikul K. Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. Southeast Asian J Trop Med Public Health. 2008; 39: 863-6.]Search in Google Scholar
[17. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. UK Collaborative HIV Cohort (CHIC) Study. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007; 370:1923-8.10.1016/S0140-6736(07)61815-7]Search in Google Scholar
[18. de Beaudrap P, Etard JF, Guèye FN, Guèye M, Landman R, Girard PM, et al; ANRS 1215/1290 Study Group. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Res Hum Retroviruses. 2008; 24:753-60.10.1089/aid.2007.029518507521]Search in Google Scholar
[19. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, et al; Asia Pacific HIV Observational Database (APHOD). Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009; 50: 513-20.10.1097/QAI.0b013e31819906d3275268119408354]Search in Google Scholar
[20. Sungkanuparph S, Chakriyanuyok T, Butthum B. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect. 2008; 56:40-3.10.1016/j.jinf.2007.10.005]Search in Google Scholar
[21. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, et al; Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 2008; 13:375-80.10.1177/135965350801300302]Search in Google Scholar
[22. Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS. 2005; 19:169-78.10.1097/00002030-200501280-00009]Open DOISearch in Google Scholar
[23. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, S˜rensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95.10.7326/0003-4819-146-2-200701160-00003]Search in Google Scholar
[24. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19.]Search in Google Scholar
[25. Supparatpinyo K, Chiewchanvit S, Hirunsri P, Uthammachai C, Nelson KE, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14: 871-4.10.1093/clinids/14.4.871]Open DOISearch in Google Scholar
[26. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4:e5575.10.1371/journal.pone.0005575]Search in Google Scholar
[27. Sterne JA, May M, Costagliola D, de Wolf F, Phillips A, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373:1352-63.10.1016/S0140-6736(09)60612-7]Search in Google Scholar
[28. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22:841-8.10.1097/QAD.0b013e3282f7cb76361846018427202]Search in Google Scholar
[29. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008; 197:1133-44.10.1086/58671318476292]Search in Google Scholar
[30. Severe P, Pape J, Fitzgerald DW. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/mL (CIPRAHT001). Presented at the 46th ICAAC, San Francisco, September, 2009 (Abstract H-1230c).]Search in Google Scholar
[31. Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, Supparatpinyo K. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res. 2009; 7: 340-5.10.2174/15701620978834790319442132]Search in Google Scholar
[32. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. 2004; 5:105-9.10.1111/j.1468-1293.2004.00195.x15012650]Search in Google Scholar
[33. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J Med Assoc Thai. 2007; 90:452-8.]Search in Google Scholar
[34. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004; 87:605-11.]Search in Google Scholar
[35. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005; 19: 1481-6.10.1097/01.aids.0000183630.27665.3016135901]Search in Google Scholar
[36. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43: 253-5.10.1086/50521016779754]Open DOISearch in Google Scholar
[37. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362:697-706.10.1056/NEJMoa0905848307622120181971]Search in Google Scholar
[38. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2006; 52:188-94.10.1016/j.jinf.2005.05.01015992932]Search in Google Scholar
[39. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006; 20: 131-2.10.1097/01.aids.0000196181.18916.9b16327334]Open DOISearch in Google Scholar
[40. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009; 48:1752-9.10.1086/59911419438397]Open DOISearch in Google Scholar
[41. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007; 44:141-4.10.1086/51007817143831]Open DOISearch in Google Scholar
[42. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Yamada N, et al. Pharmacokinetics and 48 weeks efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-Tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008; 13: 529-36.10.1177/135965350801300414]Search in Google Scholar
[43. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008; 300:555-70.10.1001/jama.300.5.55518677028]Search in Google Scholar
[44. Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, et al. Suppression of plasma viral load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347-50.10.1086/31499810479170]Search in Google Scholar
[45. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-95.10.1001/archinte.163.18.218714557216]Search in Google Scholar
[46. Mee P, Fielding KL, Charalambous S, Churchyard GL, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008; 22:1971-7.10.1097/QAD.0b013e32830e4cd818784460]Open DOISearch in Google Scholar
[47. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008; 8:89.10.1186/1471-2334-8-89245918418601727]Search in Google Scholar
[48. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009; 49:454-62.10.1086/600396485942719569972]Open DOISearch in Google Scholar
[49. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncomb C. HIV-NAT Study Team. Monitoring the toxicity of antiretroviral]Search in Google Scholar
[therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006; 58:637-44.10.1093/jac/dkl31316895939]Search in Google Scholar
[50. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Int J STD AIDS. 2007; 18:832-4.10.1258/09564620778271699218073016]Open DOISearch in Google Scholar
[51. Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J Jr. Body shape and metabolic abnormalities in Thai HIV-infected patients. AIDS Res Hum Retroviruses. 2007; 23:1314-21.10.1089/aid.2007.001318184072]Search in Google Scholar
[52. Hiransuthikul N, Hiransuthikul P, Kanasook Y. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Southeast Asian J Trop Med Public Health. 2007; 38:69-77.]Search in Google Scholar
[53. Ananworanich J, Nuesch R, Côté HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine-a Staccato trial substudy. J Antimicrob Chemother. 2008; 61:1340-3.10.1093/jac/dkn09718339636]Search in Google Scholar
[54. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic Ill). 2007; 6:36-46.10.1177/154510970629594617329503]Search in Google Scholar
[55. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 2003; 17:2129-31.10.1097/00002030-200309260-00018]Open DOISearch in Google Scholar
[56. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resourcelimited setting. J Infect. 2007; 55:464-9.10.1016/j.jinf.2007.07.002]Search in Google Scholar
[57. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009; 49:931-4.10.1086/605497]Search in Google Scholar
[58. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10:251-61.10.1016/S1473-3099(10)70026-8]Search in Google Scholar
[59. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep. 2009; 6:162-71.10.1007/s11904-009-0022-z19589302]Search in Google Scholar
[60. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007; 11: 413-6.10.1016/j.ijid.2006.11.00317331776]Open DOISearch in Google Scholar
[61. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixeddose combination of Stavudine, Lamivudine, and Nevirapine fails. Clin Infect Dis. 2007; 44:447-52.10.1086/51074517205457]Search in Google Scholar
[62. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1- infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005; 40:404-12.10.1097/01.qai.0000185314.56556.c316280694]Search in Google Scholar
[63. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill). 2006; 5:152-6.10.1177/154510970629428817101807]Search in Google Scholar
[64. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008; 41:310-3.10.1016/j.jcv.2007.12.01518316243]Search in Google Scholar
[65. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al; HOPS (HIV Outpatient Study) Investigators. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009; 151:73-84.10.7326/0003-4819-151-2-200907210-0000319620160]Search in Google Scholar
[66. Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr. 2008; 47: 429-40.10.1097/QAI.0b013e318160a52918176328]Search in Google Scholar
[67. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C. Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir +saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2007; 8: 529-35.10.1111/j.1468-1293.2007.00506.x17944686]Search in Google Scholar
[68. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingson A, et al. HIV-NAT 019 Study Team. Pharmacokinetics and short-term efficacy of a doubleboosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother. 2008; 61:1145-53.10.1093/jac/dkn05018285316]Search in Google Scholar
[69. Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2008; 47:127-9.10.1097/QAI.0b013e318157b0da236591218156991]Search in Google Scholar
[70. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17:138-45.]Search in Google Scholar
[71. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO Trial. Clin Infect Dis. 2009; 49: 1441-9.10.1086/63021019814627]Search in Google Scholar